Chapter 28
Status Epilepticus
H. Meierkord, P. Boon, B. Engelsen,
K. Göcke, S. Shorvon,
P. Tinuper, M. Holtkamp,
B. Engelsen
Haukeland University Hospital, and University of Bergen, Bergen, Norway
Search for more papers by this authorS. Shorvon
Institute of Neurology, University College London, UK
Search for more papers by this authorH. Meierkord, P. Boon, B. Engelsen,
K. Göcke, S. Shorvon,
P. Tinuper, M. Holtkamp,
B. Engelsen
Haukeland University Hospital, and University of Bergen, Bergen, Norway
Search for more papers by this authorS. Shorvon
Institute of Neurology, University College London, UK
Search for more papers by this authorNils Erik Gilhus MD, PhD,
Michael P. Barnes MD, FRCP,
Michael Brainin MD,
Nils Erik Gilhus MD, PhD
Professor
Department of Clinical Medicine, University of Bergen and Department of Neurology, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorMichael P. Barnes MD, FRCP
Professor of Neurological Rehabilitation Medical Director
University of Newcastle, Hunters Moor Neurorehabilitation Ltd, Newcastle upon Tyne, UK
Search for more papers by this authorMichael Brainin MD
Professor
Department of Clinical Medicine and Prevention, and Center for Clinical Neurosciences, Donau-Universität Krems, Department of Neurology, Landesklinikum Donauregion Tulln Tulln, Austria
Search for more papers by this authorBook Author(s):Nils Erik Gilhus MD, PhD,
Michael P. Barnes MD, FRCP,
Michael Brainin MD,
Nils Erik Gilhus MD, PhD
Professor
Department of Clinical Medicine, University of Bergen and Department of Neurology, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorMichael P. Barnes MD, FRCP
Professor of Neurological Rehabilitation Medical Director
University of Newcastle, Hunters Moor Neurorehabilitation Ltd, Newcastle upon Tyne, UK
Search for more papers by this authorMichael Brainin MD
Professor
Department of Clinical Medicine and Prevention, and Center for Clinical Neurosciences, Donau-Universität Krems, Department of Neurology, Landesklinikum Donauregion Tulln Tulln, Austria
Search for more papers by this authorFirst published: 06 September 2010
Summary
This chapter contains sections titled:
-
Background
-
Search strategy
-
Methods for reaching consensus
-
Definitions
-
Results
-
References
References
- Coeytaux A, Jallon P, Galobardes B, Morabia A. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology 2000; 55: 693–7.
- Knake S, Rosenow F, Vescovi M, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001; 42: 714–8.
- Vignatelli L, Tonon C, D'Alessandro R. Incidence and short-term prognosis of status epilepticus in adults in Bologna, Italy. Epilepsia 2003; 44: 964–8.
- Wu YW, Shek DW, Garcia PA, Zhao S, Johnston SC. Incidence and mortality of generalized convulsive status epilepticus in California. Neurology 2002; 58: 1070–6.
- Shneker BF, Fountain NB. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 2003; 61: 1066–73.
- Koubeissi M, Alshekhlee A. In-hospital mortality of generalized convulsive status epilepticus: a large US sample. Neurology 2007; 69: 886–93.
- Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 2005; 76: 534–9.
- Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59: 205–10.
- Rossetti AO, Logroscino G, Bromfi eld EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005; 62: 1698–702.
- Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006; 5: 246–56.
- Naylor DE, Liu H, Wasterlain CG. Traffi cking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 2005; 25: 7724–33.
- Wasterlain C, Liu H, Mazarati A, Baldwin R. NMDA receptor traffi cking during the transition from single seizures to status epilepticus. Ann Neurol 2002; 52 (Suppl. 1): 16.
- Snead OC, III. Basic mechanisms of generalized absence seizures. Ann Neurol 1995; 37: 146–57.
- Fountain NB. Status epilepticus: risk factors and complications. Epilepsia 2000; 41 (Suppl. 2): S23–30.
- Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientifi c task forces–revised recommendations 2004. Eur J Neurol 2004; 11: 577–81.
- Proposal for revised clinical and electroencephalographic classifi cation of epileptic seizures. From the Commission on Classifi cation and Terminology of the International League Against Epilepsy. Epilepsia 1981; 22: 489–501.
- Meldrum BS, Brierley JB. Prolonged epileptic seizures in primates. Ischemic cell change and its relation to ictal physiological events. Arch Neurol 1973; 28: 10–7.
-
Shorvon S. Status Epilepticus: Its Clinical Features and Treatment in Children and Adults. Cambridge: Cambridge University Press, 1994.
10.1017/CBO9780511526930 Google Scholar
- Theodore WH, Porter RJ, Albert P, et al. The secondarily generalized tonic-clonic seizure: a videotape analysis. Neurology 1994; 44: 1403–7.
- Jenssen S, Gracely EJ, Sperling MR. How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit. Epilepsia 2006; 47: 1499–503.
- Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the defi nition of status epilepticus. Epilepsia 1999; 40: 120–2.
- Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Eng J Med 2001; 345: 631–7.
- Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Eng J Med 1998; 339: 792–8.
- America's Working Group on Status Epilepticus. Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993; 270: 854–9. [Previous guidelines or recommendations].
- Meierkord H, Holtkamp M. Non-convulsive status epilepticus in adults: clinical forms and treatment. Lancet Neurol 2007; 6: 329–39.
- Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001; 42: 380–6.
- Lowenstein DH, Alldredge BK. Status epilepticus. N Eng J Med 1998; 338: 970–6.
- Cascino GD. Generalized convulsive status epilepticus. Mayo Clin Proc 1996; 71: 787–92.
- Hanley DF, Kross JF. Use of midazolam in the treatment of refractory status epilepticus. Clin Ther 1998; 20: 1093–105.
- Shorvon S, Baulac M, Cross H, Trinka E, Walker M. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the fi rst London Colloquium on Status Epilepticus. Epilepsia 2008; 49: 1277–85. [Previous guidelines or recommendations].
- Stecker MM, Kramer TH, Raps EC, O'Meeghan R, Dulaney E, Skaar DJ. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic fi ndings. Epilepsia 1998; 39: 18–26.
- Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983; 249: 1452–4.
- Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006; 67: 340–2.
- Gilad R, Izkovitz N, Dabby R, et al. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand 2008; 118: 296–300.
- Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus–experience in 102 adult patients. Seizure 2005; 14: 164–9.
- Walton NY. Systemic effects of generalized convulsive status epilepticus. Epilepsia 1993; 34 (Suppl. 1): S54–8.
- Holtkamp M, Matzen J, van Landeghem F, Buchheim K, Meierkord H. Transient loss of inhibition precedes spontaneous seizures after experimental status epilepticus. Neurobiol Dis 2005; 19: 162–70.
- Walker MC, Perry H, Scaravilli F, Patsalos PN, Shorvon SD, Jefferys JG. Halothane as a neuroprotectant during constant stimulation of the perforant path. Epilepsia 1999; 40: 359–64.
- Kaplan PW. No, some types of nonconvulsive status epilepticus cause little permanent neurologic sequelae (or: ‘the cure may be worse than the disease’). Neurophysiol Clin 2000; 30: 377–82.
- Holtkamp M, Othman J, Buchheim K, Masuhr F, Schielke E, Meierkord H. A ‘malignant’ variant of status epilepticus. Arch Neurol 2005; 62: 1428–31.
- Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: a survey of neurologists. J Neurol Sci 2003; 211: 37–41.
- Holtkamp M, Masuhr F, Harms L, Einhaupl KM, Meierkord H, Buchheim K. The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neurologists. J Neurol Neurosurg Psychiatry 2003; 74: 1095–9.
- Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000; 55: 722–4.
- Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007; 16: 527–32.
- Limdi NA, Shimpi AV, Faught E, Gomez CR, Burneo JG. Effi cacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005; 64: 353–5.
- Venkataraman V, Wheless JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 1999; 35: 147–53.
- Knake S, Gruener J, Hattemer K, et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008; 79: 588–9.
- Uges JW, van Huizen MD, Engelsman J, et al. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. Epilepsia 2008; 50: 415–21.
- Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of fi rst-line therapy. Epilepsy Behav 2009; 14: 429–31.
- Kaplan PW. Nonconvulsive status epilepticus. Neurology 2003; 61: 1035–6.
- Parviainen I, Uusaro A, Kalviainen R, Kaukanen E, Mervaala E, Ruokonen E. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology 2002; 59: 1249–51.
- Ulvi H, Yoldas T, Mungen B, Yigiter R. Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus. Neurol Sci 2002; 23: 177–82.
- Parviainen I, Uusaro A, Kalviainen R, Mervaala E, Ruokonen E. Propofol in the treatment of refractory status epilepticus. Intens Care Med 2006; 32: 1075–9.
- Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002; 43: 146–53.
- Bleck TP, Quigg M, Nathan BR, Smith TL, Kapur J. Electroencephalographic effects of ketamine treatment for refractory status epilepticus. Epilepsia 2002; 43 (Suppl. 1): 282.
- Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology 1998; 51: 1765–6.
- Pruss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 2008; 82: 219–22.
